“The first decision I had to make when I joined was whether to continue this anito-cel program that now looks to be potentially best-in-class in myeloma,” Rami Elghandour, CEO of Arcellx, tells Bloomberg Intelligence analyst Sam Fazeli.
“The first decision I had to make when I joined was whether to continue this anito-cel program that now looks to be potentially best-in-class in myeloma,” Rami Elghandour, CEO of Arcellx, tells Bloomberg Intelligence analyst Sam Fazeli.